

73 SB-119

June 29, 1973

Murray Weiner, M.D.
Merrill Laboratories
Amity Road
Cincinnati, Ohio 45215

Dear Murray,

I am enclosing two reports which I have completed recently, which reflect the thinking and experience with the classification of psychoactive drugs using quantitative EEG methods in volunteers. The March 23 report was presented at a symposium on phase I pharmacology; the other report is a short summary and is included because it presents additional tables, particularly Table 5.

The problem of defining an EEG profile for known antihistaminics is interesting, particularly if there is an active compound which has different CNS-behavioral effects. You will note in the report reference to the difference in EEG classification of fenfluramine when compared to dextroamphetamine-- compounds with anorexigenic activity with contrasting behavioral effects.

I will try to work up a small protocol for your review and should send it to you shortly.

Thank you for the question. My best regards.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry